Welcome to our dedicated page for Rapport Therapeutics SEC filings (Ticker: RAPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
Rapport Therapeutics describes RAP-219, an AMPAR negative allosteric modulator designed to target TARPγ8 to achieve neuroanatomical specificity for focal epilepsy and other CNS indications. In a Phase 2a safety population of 30 patients, the company reports topline efficacy in refractory focal-onset seizures: 85.2% of patients achieved ≥30% reduction in LEs and 72.0% achieved ≥50% reduction (both p<0.0001); median and higher-responder results were reported and detailed follow-up analyses are ongoing. The company states RAP-219 was generally well tolerated with four discontinuations during treatment, three attributed to TEAEs.
The filing also discloses an FDA clinical hold specific to the IND for diabetic peripheral neuropathic pain that requested protocol amendments; this hold has not affected the ongoing focal epilepsy trial. The company outlines development plans including additional follow-up results, a long-term safety trial, planned Phase 3 initiation, and further PK and PET data releases as part of its clinical pathway. The prospectus supplement stresses risks, forward-looking uncertainties, and references incorporated SEC filings for more detail.
Rapport Therapeutics (RAPP) Form 144 notice reports a proposed sale of common stock. The filer intends to sell 10,000 shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $143,600. The shares represent a portion of 36,497,920 shares outstanding. The securities were acquired and are to be sold on 09/08/2025 following an exercise of stock options, with cash payment recorded. The filer certifies no undisclosed material adverse information and provides the required Rule 144 representations.
Rapport Therapeutics, Inc. filed an 8-K stating that, effective September 8, 2025, it terminated the sales agreement prospectus tied to its Form S-3 registration statement (File No. 333-288444) for common stock sales through Leerink Partners LLC and Cantor Fitzgerald & Co.
The underlying Sales Agreement dated July 1, 2025 remains in full force and effect, but the company cannot sell common stock under it unless a new prospectus, prospectus supplement or new registration statement is filed. As of September 8, 2025, the company had not issued or sold any shares under this Sales Agreement.
Rapport Therapeutics reported topline Phase 2a efficacy for RAP-219 in drug-resistant focal onset seizures showing strong short-term clinical responses. In the 8-week treatment period, 85.2% of patients achieved a ≥30% reduction in lifetime events (LEs) from baseline, 72.0% achieved a ≥50% reduction in clinical seizures, and 24% achieved seizure freedom; all responder endpoints reported p<0.0001. Median reductions were assessed versus appropriate null hypotheses using Wilcoxon signed rank tests and exact binomial tests for responder rates.
The company said RAP-219 was generally well-tolerated with mostly mild treatment-emergent adverse events and a low discontinuation rate. Rapport noted ongoing 8-week follow-up, plans for Phase 3 trials in focal onset seizures, a Phase 2 bipolar mania study, exploration of a long-acting injectable formulation, and expects initial pharmacokinetic results in 2027. A press release and corporate presentation were furnished and a webcast presentation will be posted on the company website.
Rapport Therapeutics Chief Scientific Officer David Bredt reported sales of common stock under a Rule 10b5-1 plan adopted December 12, 2024. On 08/15/2025 he sold 8,300 shares at a weighted-average price of $14.9769 (trade prices ranged $14.65–$15.50) and sold 200 shares at a weighted-average price of $15.79 (trade prices ranged $15.74–$15.84). The filings show beneficial ownership following those transactions of 426,842 and 426,642 shares, respectively. The Form 4 was signed by attorney-in-fact Troy Ignelzi on 08/18/2025.
Rapport Therapeutics, Inc. (Nasdaq: RAPP) has filed a shelf registration statement on Form S-3 to register 470,589 existing common shares for potential resale by its principal venture investor, Sofinnova Venture Partners XI. The shares were originally issued in a $8 million private placement completed on 6 June 2024 at the IPO price of $17.00 per share. Because the shares are already outstanding, the filing does not create dilution; however, it enables Sofinnova (currently 5.1 % owner) to sell down to 3.8 % if the full allotment is distributed.
The company will receive no proceeds from any sale; it is covering an estimated $80 000 in registration expenses, while the selling shareholder will bear brokerage commissions. Following effectiveness, shares may be sold on Nasdaq, in block or negotiated trades, or via Rule 144.
Rapport is a clinical-stage biotech that applies its receptor-associated-protein (RAP) platform to neurological and psychiatric disorders. Lead asset RAP-219—an AMPA receptor negative allosteric modulator targeting TARPγ8—has completed four Phase 1 studies and is in a Phase 2a proof-of-concept trial for refractory focal epilepsy with topline data expected Q3 2025. Additional Phase 2a studies in bipolar mania (Q3 2025 start) and diabetic peripheral neuropathic pain (IND on hold) are planned. Discovery programs in α6 and α9α10 nicotinic acetylcholine receptors address chronic pain and hearing disorders. As an emerging growth and smaller reporting company, Rapport utilizes reduced SEC reporting requirements.
Overall, the filing is largely administrative, aimed at increasing float and fulfilling contractual obligations, with minimal direct financial impact on Rapport’s operations or cash runway.